studies

Extensive stage SCLC (Es-SCLC) - 1st Line (L1), Immune checkpoint association vs. placebo plus SoC, meta-analysis of study results

No data for this selection

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 162 - treatments: 856,634,861,416,864,769,980